{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:59:28Z","timestamp":1791223168589,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T00:00:00Z","timestamp":1412726400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s00228-014-1762-2","type":"journal-article","created":{"date-parts":[[2014,10,7]],"date-time":"2014-10-07T03:39:44Z","timestamp":1412653184000},"page":"1433-1441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients"],"prefix":"10.1007","volume":"70","author":[{"given":"B\u0142a\u017cej","family":"Misiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Frydecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"\u0141aczma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"\u015al\u0119zak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kiejna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,8]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","volume":"10","author":"TM Laursen","year":"2014","unstructured":"Laursen TM, Nordentoft M, Mortensen PB (2014) Excess early mortality in schizophrenia. Annu Rev Clin Psychol 10:425\u2013448. doi: 10.1146\/annurev-clinpsy-032813-153657","journal-title":"Annu Rev Clin Psychol"},{"issue":"1","key":"1762_CR2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dsx.2013.10.003","volume":"8","author":"A Bener","year":"2014","unstructured":"Bener A, Al-Hamaq AO, Dafeeah EE (2014) A twofold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Met ab Syndr 8(1):24\u201329. doi: 10.1016\/j.dsx.2013.10.003","journal-title":"Diabetes Met ab Syndr"},{"issue":"3","key":"1762_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11892-010-0112-8","volume":"10","author":"M Hasnain","year":"2010","unstructured":"Hasnain M, Fredrickson SK, Vieweg WV, Pandurangi AK (2010) Metabolic syndrome associated with schizophrenia and atypical antipsychotics. Curr Diabetes Rep 10(3):209\u2013216. doi: 10.1007\/s11892-010-0112-8","journal-title":"Curr Diabetes Rep"},{"key":"1762_CR4","author":"B Misiak","year":"2014","unstructured":"Misiak B, Frydecka D, Slezak R, Piotrowski P, Kiejna A (2014) Elevated homocysteine level in first-episode schizophrenia patients\u2014the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab Brain Dis. doi: 10.1007\/s11011-014-9534-3","journal-title":"Metab Brain Dis"},{"issue":"3","key":"1762_CR5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.psychres.2013.08.056","volume":"210","author":"S Chen","year":"2013","unstructured":"Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y (2013) Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia. Psychiatry Res 210(3):825\u2013829. doi: 10.1016\/j.psychres.2013.08.056","journal-title":"Psychiatry Res"},{"issue":"2","key":"1762_CR6","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1176\/appi.ajp.160.2.284","volume":"160","author":"MC Ryan","year":"2003","unstructured":"Ryan MC, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284\u2013289","journal-title":"Am J Psychiatry"},{"issue":"1","key":"1762_CR7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2013.07.051","volume":"150","author":"X Wu","year":"2013","unstructured":"Wu X, Huang Z, Wu R, Zhong Z, Wei Q, Wang H, Diao F, Wang J, Zheng L, Zhao J, Zhang J (2013) The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls. Schizophr Res 150(1):157\u2013162. doi: 10.1016\/j.schres.2013.07.051","journal-title":"Schizophr Res"},{"key":"1762_CR8","author":"B Garcia-Bueno","year":"2013","unstructured":"Garcia-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martinez-Cengotitabengoa M, Pina-Camacho L, Rodriguez-Jimenez R, Saiz PA, Castro C, Lafuente A, Santabarbara J, Gonzalez-Pinto A, Parellada M, Rubio G, Garcia-Portilla MP, Mico JA, Bernardo M, Leza JC (2013) Pro-\/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull. doi: 10.1093\/schbul\/sbt001","journal-title":"Schizophr Bull"},{"issue":"7","key":"1762_CR9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00406-012-0302-2","volume":"262","author":"R Ayesa-Arriola","year":"2012","unstructured":"Ayesa-Arriola R, Perez-Iglesias R, Rodriguez-Sanchez JM, Mata I, Gomez-Ruiz E, Garcia-Unzueta M, Martinez-Garcia O, Tabares-Seisdedos R, Vazquez-Barquero JL, Crespo-Facorro B (2012) Homocysteine and cognition in first-episode psychosis patients. Eur Arch Psychiatry Clin Neurosci 262(7):557\u2013564. doi: 10.1007\/s00406-012-0302-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1\u20132","key":"1762_CR10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.psychres.2009.01.013","volume":"175","author":"A Kale","year":"2010","unstructured":"Kale A, Naphade N, Sapkale S, Kamaraju M, Pillai A, Joshi S, Mahadik S (2010) Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res 175(1\u20132):47\u201353. doi: 10.1016\/j.psychres.2009.01.013","journal-title":"Psychiatry Res"},{"issue":"2","key":"1762_CR11","first-page":"141","volume":"32","author":"M Bicikova","year":"2011","unstructured":"Bicikova M, Hampl R, Hill M, Ripova D, Mohr P, Putz Z (2011) Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol Letters 32(2):141\u2013147","journal-title":"Neuro Endocrinol Letters"},{"issue":"2","key":"1762_CR12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.mp.4001746","volume":"11","author":"JW Muntjewerff","year":"2006","unstructured":"Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M (2006) Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry 11(2):143\u2013149. doi: 10.1038\/sj.mp.4001746","journal-title":"Mol Psychiatry"},{"key":"1762_CR13","author":"A Nishi","year":"2014","unstructured":"Nishi A, Numata S, Tajima A, Kinoshita M, Kikuchi K, Shimodera S, Tomotake M, Ohi K, Hashimoto R, Imoto I, Takeda M, Ohmori T (2014) Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr Bull. doi: 10.1093\/schbul\/sbt154","journal-title":"Schizophr Bull"},{"issue":"11","key":"1762_CR14","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","volume":"94","author":"SA Lipton","year":"1997","unstructured":"Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci U S A 94(11):5923\u20135928","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1762_CR15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2217\/epi.13.22","volume":"5","author":"B Misiak","year":"2013","unstructured":"Misiak B, Frydecka D, Piotrowski P, Kiejna A (2013) The multidimensional nature of metabolic syndrome in schizophrenia: lessons from studies of one-carbon metabolism and DNA methylation. Epigenomics 5(3):317\u2013329. doi: 10.2217\/epi.13.22","journal-title":"Epigenomics"},{"issue":"1","key":"1762_CR16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/schbul\/sbs139","volume":"39","author":"E Dempster","year":"2013","unstructured":"Dempster E, Viana J, Pidsley R, Mill J (2013) Epigenetic studies of schizophrenia: progress, predicaments, and promises for the future. Schizophr Bull 39(1):11\u201316. doi: 10.1093\/schbul\/sbs139","journal-title":"Schizophr Bull"},{"issue":"12","key":"1762_CR17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/gm397","volume":"4","author":"M Nishioka","year":"2012","unstructured":"Nishioka M, Bundo M, Kasai K, Iwamoto K (2012) DNA methylation in schizophrenia: progress and challenges of epigenetic studies. Genome Med 4(12):96. doi: 10.1186\/gm397","journal-title":"Genome Med"},{"issue":"3","key":"1762_CR18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.psychres.2013.08.016","volume":"210","author":"V Geller","year":"2013","unstructured":"Geller V, Friger M, Sela BA, Levine J (2013) Elevated homocysteine level in siblings of patients with schizophrenia. Psychiatry Res 210(3):769\u2013772. doi: 10.1016\/j.psychres.2013.08.016","journal-title":"Psychiatry Res"},{"issue":"4","key":"1762_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2217\/pgs.13.220","volume":"15","author":"SN Roffeei","year":"2014","unstructured":"Roffeei SN, Mohamed Z, Reynolds GP, Said MA, Hatim A, Mohamed EH, Aida SA, Zainal NZ (2014) Association of FTO, LEPR and MTHFR gene polymorphisms with metabolic syndrome in schizophrenia patients receiving antipsychotics. Pharmacogenomics 15(4):477\u2013485. doi: 10.2217\/pgs.13.220","journal-title":"Pharmacogenomics"},{"issue":"2","key":"1762_CR20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/JCP.0b013e3182485888","volume":"32","author":"VL Ellingrod","year":"2012","unstructured":"Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zollner SK, Pop-Busui R (2012) Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. J Clin Psychopharmacol 32(2):261\u2013265. doi: 10.1097\/JCP.0b013e3182485888","journal-title":"J Clin Psychopharmacol"},{"issue":"1\u20133","key":"1762_CR21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.schres.2010.05.030","volume":"121","author":"R Winkel van","year":"2010","unstructured":"van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M (2010) MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121(1\u20133):193\u2013198. doi: 10.1016\/j.schres.2010.05.030","journal-title":"Schizophr Res"},{"issue":"5","key":"1762_CR22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/YIC.0b013e32833bc60d","volume":"25","author":"R Winkel van","year":"2010","unstructured":"van Winkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M (2010) MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25(5):270\u2013276. doi: 10.1097\/YIC.0b013e32833bc60d","journal-title":"Int Clin Psychopharmacol"},{"key":"1762_CR23","doi-asserted-by":"crossref","unstructured":"Srisawat U, Reynolds GP, Zhang ZJ, Zhang XR, Arranz B, San L, Dalton CF (2013) Methylenetetrahydrofolate reductase (MTHFR) 677C\/T polymorphism is associated with antipsychotic-induced weight gain in first-episode schizophrenia. Int J Neuropsychopharmacol:1-6. doi: 10.1017\/S1461145713001375","DOI":"10.1017\/S1461145713001375"},{"issue":"1\u20133","key":"1762_CR24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2007.09.030","volume":"98","author":"VL Ellingrod","year":"2008","unstructured":"Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J (2008) Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C\/T and 1298A\/C variants. Schizophr Res 98(1\u20133):47\u201354. doi: 10.1016\/j.schres.2007.09.030","journal-title":"Schizophr Res"},{"issue":"8","key":"1762_CR25","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/archpsyc.1991.01810320088015","volume":"48","author":"P McGuffin","year":"1991","unstructured":"McGuffin P, Farmer A, Harvey I (1991) A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system Archives of general psychiatry 48(8):764\u2013770","journal-title":"Development and reliability of the OPCRIT system Archives of general psychiatry"},{"issue":"2","key":"1762_CR26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261\u2013276","journal-title":"Schizophr Bull"},{"issue":"4","key":"1762_CR27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0899-3289(20)30011-0","volume":"1","author":"CS Pomerleau","year":"1989","unstructured":"Pomerleau CS, Majchrzak MJ, Pomerleau OF (1989) Nicotine dependence and the Fagerstrom tolerance questionnaire: a brief review. J Subst Abus 1(4):471\u2013477","journal-title":"J Subst Abus"},{"issue":"11\u201312","key":"1762_CR28","first-page":"513","volume":"56","author":"E Eren","year":"2010","unstructured":"Eren E, Yegin A, Yilmaz N, Herken H (2010) Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clinical Laboratory 56(11\u201312):513\u2013518","journal-title":"Clinical Laboratory"},{"issue":"5","key":"1762_CR29","doi-asserted-by":"crossref","first-page":"e65719","DOI":"10.1371\/journal.pone.0065719","volume":"8","author":"ML Lu","year":"2013","unstructured":"Lu ML, Lin CH, Chen YC, Yang HC, Wu TH (2013) Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. PLoS One 8(5):e65719. doi: 10.1371\/journal.pone.0065719","journal-title":"PLoS One"},{"issue":"5","key":"1762_CR30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/08039488.2012.745601","volume":"67","author":"B Vuksan-Cusa","year":"2013","unstructured":"Vuksan-Cusa B, Sagud M, Jakovljevic M, Peles AM, Jaksic N, Mihaljevic S, Zivkovic M, Mikulic SK, Jevtovic S (2013) Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia. Nordic J Psychiatr 67(5):320\u2013325. doi: 10.3109\/08039488.2012.745601","journal-title":"Nordic J Psychiatr"},{"issue":"1","key":"1762_CR31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2010.11.021","volume":"189","author":"B Vuksan-Cusa","year":"2011","unstructured":"Vuksan-Cusa B, Jakovljevic M, Sagud M, Mihaljevic Peles A, Marcinko D, Topic R, Mihaljevic S, Sertic J (2011) Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics. Psychiatry Res 189(1):21\u201325. doi: 10.1016\/j.psychres.2010.11.021","journal-title":"Psychiatry Res"},{"issue":"9690","key":"1762_CR32","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374(9690):620\u2013627. doi: 10.1016\/S0140-6736(09)60742-X","journal-title":"Lancet"},{"key":"1762_CR33","volume":"1","author":"K Komossa","year":"2011","unstructured":"Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, Leucht S (2011) Risperidone versus other atypical antipsychotics for schizophrenia. The Cochrane Database of Systematic Reviews 1, CD006626. doi: 10.1002\/14651858.CD006626.pub2","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"1\u20133","key":"1762_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2009.03.025","volume":"111","author":"JK Patel","year":"2009","unstructured":"Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA (2009) Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 111(1\u20133):9\u201316. doi: 10.1016\/j.schres.2009.03.025","journal-title":"Schizophr Res"},{"issue":"11","key":"1762_CR35","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.4088\/JCP.v68n1113","volume":"68","author":"R Perez-Iglesias","year":"2007","unstructured":"Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL (2007) A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. The J Clin Psychiatry 68(11):1733\u20131740","journal-title":"The J Clin Psychiatry"},{"issue":"1","key":"1762_CR36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S1461145713001053","volume":"17","author":"R Perez-Iglesias","year":"2014","unstructured":"Perez-Iglesias R, Martinez-Garcia O, Pardo-Garcia G, Amado JA, Garcia-Unzueta MT, Tabares-Seisdedos R, Crespo-Facorro B (2014) Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. Int J Neuropsychopharmacol 17(1):41\u201351. doi: 10.1017\/S1461145713001053","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"1762_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1868-7083-6-1","volume":"6","author":"MG Melka","year":"2014","unstructured":"Melka MG, Laufer BI, McDonald P, Castellani CA, Rajakumar N, O'Reilly R, Singh SM (2014) The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum. Clin Epigenetics 6(1):1. doi: 10.1186\/1868-7083-6-1","journal-title":"Clin Epigenetics"},{"issue":"8","key":"1762_CR38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1177\/0269881107077609","volume":"21","author":"A Sarandol","year":"2007","unstructured":"Sarandol A, Kirli S, Akkaya C, Ocak N, Eroz E, Sarandol E (2007) Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment. J Psychopharmacol 21(8):857\u2013863. doi: 10.1177\/0269881107077609","journal-title":"J Psychopharmacol"},{"issue":"8","key":"1762_CR39","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/j.pnpbp.2008.09.009","volume":"32","author":"ND Petronijevic","year":"2008","unstructured":"Petronijevic ND, Radonjic NV, Ivkovic MD, Marinkovic D, Piperski VD, Duricic BM, Paunovic VR (2008) Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(8):1921\u20131926. doi: 10.1016\/j.pnpbp.2008.09.009","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"10","key":"1762_CR40","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1007\/s11064-013-1113-1","volume":"38","author":"A Wysokinski","year":"2013","unstructured":"Wysokinski A, Kloszewska I (2013) Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochem Res 38(10):2056\u20132062. doi: 10.1007\/s11064-013-1113-1","journal-title":"Neurochem Res"},{"issue":"3","key":"1762_CR41","doi-asserted-by":"crossref","first-page":"e33222","DOI":"10.1371\/journal.pone.0033222","volume":"7","author":"M Yakub","year":"2012","unstructured":"Yakub M, Moti N, Parveen S, Chaudhry B, Azam I, Iqbal MP (2012) Polymorphisms in MTHFR, MS and CBS genes and homocysteine levels in a Pakistani population. PLoS One 7(3):e33222. doi: 10.1371\/journal.pone.0033222","journal-title":"PLoS One"},{"issue":"1","key":"1762_CR42","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.psychres.2010.04.008","volume":"179","author":"N Bouaziz","year":"2010","unstructured":"Bouaziz N, Ayedi I, Sidhom O, Kallel A, Rafrafi R, Jomaa R, Melki W, Feki M, Kaabechi N, El Hechmi Z (2010) Plasma homocysteine in schizophrenia: determinants and clinical correlations in Tunisian patients free from antipsychotics. Psychiatry Res 179(1):24\u201329. doi: 10.1016\/j.psychres.2010.04.008","journal-title":"Psychiatry Res"},{"issue":"9","key":"1762_CR43","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1176\/appi.ajp.162.9.1738","volume":"162","author":"G Neeman","year":"2005","unstructured":"Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U (2005) Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry 162(9):1738\u20131740. doi: 10.1176\/appi.ajp.162.9.1738","journal-title":"Am J Psychiatry"},{"issue":"9","key":"1762_CR44","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1176\/appi.ajp.161.9.1705","volume":"161","author":"DC Goff","year":"2004","unstructured":"Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J (2004) Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 161(9):1705\u20131708. doi: 10.1176\/appi.ajp.161.9.1705","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1762_CR45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/schbul\/sbr150","volume":"39","author":"JL Roffman","year":"2013","unstructured":"Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC (2013) Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Schizophr Bull 39(2):330\u2013338. doi: 10.1093\/schbul\/sbr150","journal-title":"Schizophr Bull"},{"issue":"1","key":"1762_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.biopsych.2006.12.017","volume":"63","author":"JL Roffman","year":"2008","unstructured":"Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Bottiglieri T, Wong DH, Halsted CH, Goff DC (2008) Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry 63(1):42\u201348. doi: 10.1016\/j.biopsych.2006.12.017","journal-title":"Biol Psychiatry"},{"key":"1762_CR47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","volume":"10","author":"P Chue","year":"2014","unstructured":"Chue P, Lalonde JK (2014) Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options. Neuropsychiatr Dis Treat 10:777\u2013789. doi: 10.2147\/NDT.S43404","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"1762_CR48","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","volume":"37","author":"P Fusar-Poli","year":"2013","unstructured":"Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37(8):1680\u20131691. doi: 10.1016\/j.neubiorev.2013.06.001","journal-title":"Neurosci Biobehav Rev"},{"key":"1762_CR49","doi-asserted-by":"crossref","unstructured":"Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC (2011) Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophrenia research 127 (1-3):41-45. doi: 10.1016\/j.schres.2010.12.006","DOI":"10.1016\/j.schres.2010.12.006"},{"issue":"5","key":"1762_CR50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2013.900","volume":"70","author":"JL Roffman","year":"2013","unstructured":"Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC (2013) Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia. JAMA Psychiatry 70(5):481\u2013489. doi: 10.1001\/jamapsychiatry.2013.900","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"1762_CR51","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1176\/appi.ajp.159.10.1790","volume":"159","author":"J Levine","year":"2002","unstructured":"Levine J, Stahl Z, Sela BA, Gavendo S, Ruderman V, Belmaker RH (2002) Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 159(10):1790\u20131792","journal-title":"Am J Psychiatry"},{"issue":"4","key":"1762_CR52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jpsychires.2004.01.003","volume":"38","author":"J Applebaum","year":"2004","unstructured":"Applebaum J, Shimon H, Sela BA, Belmaker RH, Levine J (2004) Homocysteine levels in newly admitted schizophrenic patients. J Psychiatr Res 38(4):413\u2013416. doi: 10.1016\/j.jpsychires.2004.01.003","journal-title":"J Psychiatr Res"},{"issue":"6","key":"1762_CR53","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2796.1994.tb00856.x","volume":"236","author":"L Brattstrom","year":"1994","unstructured":"Brattstrom L, Lindgren A, Israelsson B, Andersson A, Hultberg B (1994) Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J Intern Med 236(6):633\u2013641","journal-title":"J Intern Med"},{"issue":"19","key":"1762_CR54","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1001\/jama.1995.03530190040032","volume":"274","author":"O Nygard","year":"1995","unstructured":"Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G (1995) Total plasma homocysteine and cardiovascular risk profile the hordaland homocysteine study JAMA. J Am Med Assoc 274(19):1526\u20131533","journal-title":"J Am Med Assoc"},{"issue":"4","key":"1762_CR55","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1743-6109.2007.00646.x","volume":"5","author":"LJ Gooren","year":"2008","unstructured":"Gooren LJ, Giltay EJ (2008) Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sexual Medicine 5(4):765\u2013776. doi: 10.1111\/j.1743-6109.2007.00646.x","journal-title":"J Sexual Medicine"},{"issue":"7","key":"1762_CR56","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/clinchem\/38.7.1311","volume":"38","author":"A Andersson","year":"1992","unstructured":"Andersson A, Isaksson A, Hultberg B (1992) Homocysteine export from erythrocytes and its implication for plasma sampling. Clin Chem 38(7):1311\u20131315","journal-title":"Clin Chem"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1762-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1762-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1762-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T03:57:51Z","timestamp":1650340671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1762-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,8]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1762-2","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,8]]}}}